Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

Abstract: A synthetic magnesium silicate composition of the formula: {[Si8(MgaLib)O20(OH)4-cFc]d?d/nMn+}w{Na2SO4}x{Na2CO3}y{H2O}z where a is 4.5 to <6.0, b is from >0 to 1.5, c is from 0 to 4, d=12?2a?b, M is a cation, n is the valency of cation M, w is from 32.8 to 94.7 wt. %, x is from 0.3 to 32.0 wt. %, y is from 0 to 9.0 wt. %, and z is from 0 to 50 wt.

Abstract: A synthetic layered silicate material may be produced which exhibits tolerance to high levels of electrolytes and surfactants as measured by viscosity, hydration rate and clarity. The synthetic layered silicate material may produce similar or improved rheological properties when compared to natural hectorite at comparable or lower addition rates in select aqueous systems.